The report covers emerging Lyme Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Lyme Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Lyme Disease: An Overview
Lyme disease (LD) is primarily caused by the spirochete Borrelia burgdorferi, which enters the bloodstream through the bite of an infected tick after the tick has been attached for 48–72 hours. It stands as the most prevalent vector-borne illness. The way it manifests clinically varies depending on the stage of the disease, encompassing symptoms such as erythema migrans, carditis, central nervous system complications, and arthritis. Irrespective of the particular clinical presentation, the majority of Lyme Disease patients experience a resolution of their symptoms when they receive the appropriate antimicrobial treatment. Persistent symptoms after treatment typically result more from misdiagnosis rather than a failure of the treatment itself.
Randomized controlled trials have ascertained the efficiency of antibiotics in treating erythema migrans, the hallmark of early-stage Lyme borreliosis. Oral amoxicillin and doxycycline are first-line treatment options, though phenoxymethylpenicillin, cefuroxime axetil, and azithromycin are alternative second-line options. Treatments for secondary and tertiary Lyme borreliosis are more poorly documented, and antibiotics are not always effective. Pinpointing the absence of any reliable method of diagnosis, it is difficult to choose the proper treatment and to evaluate treatment efficacy.
However, numerous studies have shown that ceftriaxone and doxycycline are the most efficient antibiotics, particularly in Lyme arthritis and neuroborreliosis. In late Lyme borreliosis, these antibiotics were less efficient, and different treatment schemes with variations in dosage or duration did not produce convincing results.
Lyme Disease Market Key Facts
- According to Mead (2015), Lyme disease has been a nationally notifiable condition in the United States since 1991. Case definitions are revised periodically, as in 1996 to clarify laboratory criteria and again in 2008 to allow reporting of probable cases.
- As per the Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), and Division of Vector-Borne Diseases (DVBD), recent estimates using other methods suggest that approximately 476,000 people may get Lyme disease each year in the United States.
- As per the United States Environmental Protection Agency, the incidence of Lyme disease in the United States has nearly doubled since 1991, from 3.74 reported cases per 100,000 people to 7.21 reported cases per 100,000 people in 2018.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Lyme Disease pipeline therapies. It also thoroughly assesses the Lyme Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Lyme Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Lyme Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Lyme Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Lyme Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Lyme Disease Epidemiology, Segmented as –
- Total incident population of Lyme disease
- Gender-specific incidence of Lyme disease
- Total diagnosed population of Lyme disease
- Acute and chronic incidence of Lyme disease
- Age-specific diagnosed incidence of Lyme disease
Lyme Disease Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Lyme Disease market or expected to be launched during the study period. The analysis covers the Lyme Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Lyme Disease drugs based on their sale and market share.
The report also covers the Lyme Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Lyme Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Lyme Disease Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/lyme-disease-ld-market
Lyme Disease Therapeutics Analysis
The treatment of Lyme disease varies according to the clinical stage. For each stage, the pathophysiology differs, and therefore the antibiotherapy has to be adapted to the clinical signs. Recently published guidelines and recommendations follow this strategy, in order to help choose the best antibiotics for each clinical situation.
There are no vaccines currently being marketed for Lyme disease. There is now a greater demand for Lyme disease vaccines. This is due to the rise in infections in the US and Europe, arising from factors such as climate change. Alongside predominant dive in prevention by various leading names, Moderna’s recent interest in the condition raises the prospect of additional prophylactic options over the longer term.
Several major pharma and biotech companies are developing therapies for Lyme Disease. Currently, Valneva is leading the therapeutics market with its Lyme Disease drug candidates in the most advanced stage of clinical development.
Lyme Disease Companies Actively Working in the Therapeutics Market Include
There are no vaccines currently being marketed for Lyme disease. There is now a greater demand for Lyme disease vaccines. This is due to the rise in infections in the US and Europe, arising from factors such as climate change. Alongside predominant dive in prevention by various leading names, Moderna’s recent interest in the condition raises the prospect of additional prophylactic options over the longer term.
To improve the treatment scenario, some of the key companies such as Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics, Pfizer, Moderna, and others are actively working in the Lyme Disease Market.
Emerging and Marketed Lyme Disease Therapies Covered in the Report Include:
- CT38: Cortene
- VLA-15: Valneva/Pfizer
- TP-05: Tarsus Pharmaceuticals Inc.
- mRNA-1982 and mRNA-1975: Moderna
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/lyme-disease-ld-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Lyme Disease Competitive Intelligence Analysis
4. Lyme Disease Market Overview at a Glance
5. Lyme Disease Disease Background and Overview
6. Lyme Disease Patient Journey
7. Lyme Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Lyme Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Lyme Disease Unmet Needs
10. Key Endpoints of Lyme Disease Treatment
11. Lyme Disease Marketed Therapies
12. Lyme Disease Emerging Drugs and Latest Therapeutic Advances
13. Lyme Disease Seven Major Market Analysis
14. Attribute Analysis
15. Lyme Disease Market Outlook (In US, EU5, and Japan)
16. Lyme Disease Companies Active in the Market
17. Lyme Disease Access and Reimbursement Overview
18. KOL Views on the Lyme Disease Market
19. Lyme Disease Market Drivers
20. Lyme Disease Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/lyme-disease-ld-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Lichen Planus Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Lichen Planus market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Lichen Planus market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research